Tec-Dara Could Represent a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hemat…

Teclistamab combination confers ‘unprecedented’ benefit for relapsed, refractory myeloma

ORLANDO — “The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for disease progression or death 83% from standard daratumumab and dexamethasone with either pomalidomide or bortezomib, according to findings of a randomized phase 3

Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hemat…

Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and...

Unprecedented Results from the Phase 3 MajesTEC-3 study Support TECVAYLI® plus DARZALEX FASPRO® as a Potential Standard of Care as Early as Second line for Patients with Relapsed/Refractory Multiple Myeloma - Life Sciences British Columbia

Orlando, Fla. – Johnson & Johnson, announced new data from the Phase 3 MajesTEC-3 study demonstrating TECVAYLI® and DARZALEX FASPRO®.